How pembrolizumab reset the bar for advanced melanoma: what KEYNOTE-006 showed
In a randomized phase 3 trial, the anti-PD-1 antibody pembrolizumab improved survival over ipilimumab in advanced melanoma, helping establish PD-1 blockade as a frontline immunotherapy.
What the study found
KEYNOTE-006 was a randomized, phase 3 trial that compared pembrolizumab — an antibody that blocks the PD-1 immune checkpoint — against ipilimumab, an anti-CTLA-4 antibody that was then a standard immunotherapy, in patients with advanced (unresectable or metastatic) melanoma. Patients received one of two pembrolizumab dosing schedules or ipilimumab. Pembrolizumab improved both progression-free survival and overall survival compared with ipilimumab, and did so with a lower rate of severe (high-grade) treatment-related side effects.
How the two drugs differ
Both drugs are immunotherapies, but they release different brakes on the immune system. Ipilimumab targets CTLA-4, a checkpoint that acts early in T-cell activation. Pembrolizumab targets PD-1, a checkpoint that tumors exploit later, inside the tissue, to switch off T cells that have already recognized them. Blocking PD-1 lets those T cells keep attacking the tumor.
Why it matters
Before checkpoint inhibitors, metastatic melanoma had few durable treatment options. Results like KEYNOTE-006 helped move PD-1 blockade to the front line for advanced melanoma and informed the broader use of checkpoint inhibitors across many cancer types. The U.S. National Cancer Institute now lists checkpoint inhibitors among standard immunotherapy approaches.
What is still uncertain
A trial result describes averages across a studied population, not any one person's outcome. Checkpoint inhibitors do not work for everyone; responses vary by tumor type and biomarker status, and they carry immune-related side effects that require medical monitoring. Which patients benefit most, and how best to combine or sequence these drugs, remains an active research question.